Next Article in Journal
Children with Autism Spectrum Disorder and Abnormalities of Clinical EEG: A Qualitative Review
Previous Article in Journal
Optimal Antithrombotic Strategies in Cardiogenic Shock
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 13
Issue 1
10.3390/jcm13010278
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside

by
Pojsakorn Danpanichkul
1,*,†,
Kanokphong Suparan
1,†,
Donghee Kim
2 and
Karn Wijarnpreecha
3,4,*
1
Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand
2
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA
3
Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ 85004, USA
4
Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ 85006, USA
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work as co-first authors.
J. Clin. Med. 2024, 13(1), 278; https://doi.org/10.3390/jcm13010278
Submission received: 1 December 2023 / Revised: 2 January 2024 / Accepted: 2 January 2024 / Published: 3 January 2024
(This article belongs to the Section Gastroenterology & Hepatopancreatobiliary Medicine)
Browse Figures
Versions Notes

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects more than 30% of the world’s adult population. While it is associated with obesity and metabolic syndrome, emerging evidence has shown that a substantial number of MASLD patients have a normal body mass index (“lean individuals with MASLD”). In this article, we provide an overview of the definition, epidemiology, pathogenesis, and clinical outcomes associated with lean individuals with MASLD and updates on current management.
Keywords: metabolic dysfunction-associated steatotic liver disease; liver disease; metabolic syndrome; lean metabolic dysfunction-associated steatotic liver disease; liver disease; metabolic syndrome; lean

Share and Cite

MDPI and ACS Style

Danpanichkul, P.; Suparan, K.; Kim, D.; Wijarnpreecha, K. What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside. J. Clin. Med. 2024, 13, 278. https://doi.org/10.3390/jcm13010278

AMA Style

Danpanichkul P, Suparan K, Kim D, Wijarnpreecha K. What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside. Journal of Clinical Medicine. 2024; 13(1):278. https://doi.org/10.3390/jcm13010278

Chicago/Turabian Style

Danpanichkul, Pojsakorn, Kanokphong Suparan, Donghee Kim, and Karn Wijarnpreecha. 2024. "What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside" Journal of Clinical Medicine 13, no. 1: 278. https://doi.org/10.3390/jcm13010278

APA Style

Danpanichkul, P., Suparan, K., Kim, D., & Wijarnpreecha, K. (2024). What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside. Journal of Clinical Medicine, 13(1), 278. https://doi.org/10.3390/jcm13010278

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop